Industry News

International Society for Pharmaceutical Engineering will continue strategic plan initiated by Nancy Berg; search begins for replacement.

EMD Millipore's expands its Emprove raw materials portfolio to include 400 products.

PharmaCell enters an agreement purchase TiGenix therapy production facility.

Novozymes Biopharma has released new study data on extending the serum half-life of albumin in vivo.

FDA adds Ranbaxy's Toansa, India facility to existing consent decree, prohibiting distribution of APIs from that location

In 2013, the EMA's Committee for Medicinal Products for Human Use recommended 81 medicines for human use for marketing authorization, compared with 57 in 2012.

The Stevens Institute of Technology will open a new biotechnology laboratory in January 2014.

Combined technologies from Agilent Technologies and Picometrics Technologies are designed for large–molecule analysis.

Novasep selects Thierry van Nieuwenhove as new president of the synthesis business unit.

USP opens expanded Shanghai facility to enhance quality standards for medicines and food ingredients.

CCBR–SYNARC and BioClinica merge to create a provider of specialized outsourced clinical services.

A packaging defect has led to Merck voluntarily recalling all lots of Liptruzet tablets in the United States.

CytomX Therapeutics and ImmunoGen announce collaboration to develop probody-drug conjugate therapies for the treatment of cancer.

Eurofins acquires DDS business of Merck KGaA in order to expand discovery solutions and bioanalytical services.

LSNE completes an FDA inspection of its Manchester manufacturing facility.Lyophilization Services of New England (LSNE),

Genzyme plans to appeal FDA?s decision that the multiple-sclerosis treatment is not ready for approval.

Baxter International recalls dextrose injection and four sodium chloride injections.

Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI's LifeSciences business unit for $185 million.

Merck and GlaxoSmithKline begin clinical trial of pazopanib for the treatment of advanced renal-cell carcinoma.

Bind Therapeutics amends its development and commercialization collaboration agreement with Amgen.

CMC Biologics and OnoSynergy form an agreement from cell-line development.

Pfizer appoints management changes to take effect in 2014.

Leidos Holdings awards Pfenex a subcontract in support of the development of an anthrax vaccine.

Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.

ProBioGen signs agreement with Emergent BioSolutions for access to ProBioGen's avian AGE1.CR cell line.

Almost 400 new medicines for infectious diseases, including viral infections, bacterial infections, fungal infections and parasitic infections.

Johnson&Johnson will open a network of partnering offices across the UK.

BioWa and Lonza have entered into a licensing agreement with MedImmune for cell line technology.